However, P450s were largely overlooked in the development of cancer drugs until recently, recognized only for their role in the chemotherapeutic metabolism of Phase I. The first successful strategy in cancer therapy to target P450s was the production of active CYP19 (aromatase) inhibitors for the treatment of breast cancer. Here, CYP19A1 is linked to breast cancer.